Shooshtari Ariana Azimi, Jayaraman Elakiya Anjali, Kesavan Ramesh, Sarva Siva, Manjunath Skantha, Patel Azad
College of Liberal Arts, University of Texas at Austin, Austin, USA.
Pulmonary and Critical Care Medicine and Internal Medicine, HCA Houston Healthcare Kingwood/University of Houston, Kingwood, USA.
Cureus. 2025 Aug 2;17(8):e89263. doi: 10.7759/cureus.89263. eCollection 2025 Aug.
Pulmonary toxicity is a serious yet frequently under-recognized complication of antidepressant therapy. With the continued rise in prescriptions, awareness of potential respiratory adverse effects is crucial. This review outlines documented cases of lung injury linked to various antidepressant classes, including selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), atypical antidepressants, serotonin modulators, tricyclic antidepressants (TCAs), and monoamine oxidase inhibitors (MAOIs). A wide range of manifestations, such as interstitial lung disease, eosinophilic pneumonia, acute respiratory distress syndrome, and alveolar hemorrhage, occurring at both standard dosages and in overdose situations, have been documented. Clinicians should remain vigilant for respiratory symptoms emerging during treatment and pursue timely evaluation and management to minimize the risk of long-term pulmonary complications and improve clinical outcomes.
肺部毒性是抗抑郁治疗中一种严重但常未被充分认识的并发症。随着处方量持续增加,认识到潜在的呼吸不良反应至关重要。本综述概述了与各类抗抑郁药相关的肺损伤病例记录,包括选择性5-羟色胺再摄取抑制剂(SSRI)、5-羟色胺-去甲肾上腺素再摄取抑制剂(SNRI)、非典型抗抑郁药、5-羟色胺调节剂、三环类抗抑郁药(TCA)和单胺氧化酶抑制剂(MAOI)。已记录到在标准剂量和过量情况下出现的一系列表现,如间质性肺疾病、嗜酸性粒细胞性肺炎、急性呼吸窘迫综合征和肺泡出血。临床医生应警惕治疗期间出现的呼吸道症状,并及时进行评估和处理,以将长期肺部并发症的风险降至最低并改善临床结局。